A first-in-human phase 1/1b study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors

被引：0
|
作者：
Schwartz, G. [1 ]
Adkins, D. [2 ]
Heist, R. [3 ]
Werner, T. [4 ]
Abbott, M. [1 ]
Barber, S. [2 ]
Slusarz, K. [3 ]
Agarwal, N. [4 ]
Neuteboom, S. [5 ]
Faltaos, D. [5 ]
Chen, I. [5 ]
Christensen, J. [6 ]
Chao, R. [5 ]
Bauer, T. [7 ]
机构：
[1] Columbia Univ, Div Hematol & Oncol, Med Ctr, New York, NY USA
[2] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[3] Massachusetts Gen Hosp, Ctr Canc, Hematol Oncol, Boston, MA USA
[4] Huntsman Canc Inst, Div Oncol, Salt Lake City, UT USA
[5] Mirati Therapeut, Clin Sci, San Diego, CA USA
[6] Mirati Therapeut, Discovery & Translat Sci, San Diego, CA USA
[7] Tennessee Oncol PLLC, Oncol, Sarah Cannon Res Inst, Nashville, TN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30233-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [1] A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
    Schwartz, Gary K.
    Adkins, Douglas
    Heist, Rebecca Suk
    Abbott, Maura
    Barber, Stephanie L.
    Chao, Richard C.
    Neuteboom, Saskia T. C.
    Chen, Isan
    Christensen, James
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
    Bauer, Todd Michael
    Adkins, Douglas
    Schwartz, Gary K.
    Werner, Theresa Louise
    Alva, Ajjai Shivaram
    Hong, David S.
    Carvajal, Richard D.
    Saleh, Mansoor N.
    Bazhenova, Lyudmila
    Goel, Sanjay
    Eaton, Keith D.
    Siegel, Robert D.
    Wang, Ding
    Lauer, Richard C.
    Neuteboom, Saskia T. C.
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Chao, Richard C.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors
    Werner, Theresa
    Heist, Rebecca
    Carvajal, Richard
    Adkins, Douglas
    Alva, Ajjai
    Goe, Sanjay
    Hong, David
    Bazhenova, Lyudmila
    Saleh, Mansoor
    Siegel, Robert
    Kyriakopoulos, Christos
    Blakely, Collin
    Eaton, Keith
    Lauer, Richard
    Wang, Ding
    Schwartz, Gary
    Neuteboom, Saskia
    Potvin, Diane
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Levisetti, Matteo
    Chao, Richard
    Bauer, Todd
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1068 - S1069
  • [4] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
    Bauer, Todd
    Cho, Byong Chul
    Heist, Rebecca
    Bazhenova, Lyudmila
    Werner, Theresa
    Goel, Sanjay
    Kim, Dong-Wan
    Adkins, Douglas
    Carvajal, Richard D.
    Alva, Ajjai
    Eaton, Keith
    Wang, Judy
    Liu, Yong
    Yan, Xiaohong
    Christensen, Jamie
    Neuteboom, Saskia
    Chao, Richard
    Pant, Shubham
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 990 - 1000
  • [5] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
    Todd Bauer
    Byong Chul Cho
    Rebecca Heist
    Lyudmila Bazhenova
    Theresa Werner
    Sanjay Goel
    Dong-Wan Kim
    Douglas Adkins
    Richard D. Carvajal
    Ajjai Alva
    Keith Eaton
    Judy Wang
    Yong Liu
    Xiaohong Yan
    Jamie Christensen
    Saskia Neuteboom
    Richard Chao
    Shubham Pant
    Investigational New Drugs, 2022, 40 : 990 - 1000
  • [6] Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
    Kollmannsberger, Christian K.
    Sharma, Sunil
    Shapiro, Geoffrey
    Chi, Kim N.
    Christensen, James
    Tassell, Vanessa Roberts
    Chao, Richard C.
    Faltaos, Demiana
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors
    Sharma, Sunil
    Shapiro, Geoffrey
    Kollmannsberger, Christian K.
    Christensen, James
    Tassell, Vanessa Roberts
    Faltaos, Demiana
    Chao, Richard C.
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
    Frentzas, Sophia
    Gan, Hui K.
    Cosman, Rasha
    Coward, Jermaine
    Tran, Ben
    Millward, Michael
    Zhou, Yiting
    Wang, Wenjing
    Xia, Dennis
    Wang, Zhongmin Maxwell
    Li, Baiyong
    Xia, Michelle
    Desai, Jayesh
    CELL REPORTS MEDICINE, 2023, 4 (11)
  • [9] A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
    Shinji Nakamichi
    Hiroshi Nokihara
    Noboru Yamamoto
    Yasuhide Yamada
    Kazunori Honda
    Yosuke Tamura
    Hiroshi Wakui
    Tatsuya Sasaki
    Wataru Yusa
    Katsuki Fujino
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1153 - 1161
  • [10] A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
    Nakamichi, Shinji
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Honda, Kazunori
    Tamura, Yosuke
    Wakui, Hiroshi
    Sasaki, Tatsuya
    Yusa, Wataru
    Fujino, Katsuki
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1153 - 1161
12345